All In Biotech

Drug Trial Radar · NCT01674621

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal) in Healthy Postmenopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Jun 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Sep 25, 2012

Primary completion

Aug 2, 2013

Study completion Aug 2, 2013

Sponsor

Lead sponsor
Radius Health, Inc.Industry
Sponsor type
Industry
Collaborators
Nordic Bioscience A/S
First posted
Aug 29, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 months of treatment.

Conditions

  • Post Menopausal Osteoporosis

Interventions

  • Abaloparatide Transdermal (50 mcg)Drug

    Abaloparatide Transdermal Microneedle Active Patch

  • Abaloparatide Transdermal (100 mcg)Drug

    Abaloparatide Transdermal Microneedle Active Patch

  • Abaloparatide Transdermal (150 mcg)Drug

    Abaloparatide Transdermal Microneedle Active Patch

  • Abaloparatide Injection (80 mcg)Drug

    Abaloparatide Subcutaneous Injection

  • Abaloparatide PlaceboDrug

    Abaloparatide Transdermal Microneedle Placebo Patch

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 MonthsTime frame: Baseline, 6 Months

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Lakewood, Colorado

  • Site not named

    Atlanta, Georgia

  • Site not named

    Bethesda, Maryland

  • Site not named

    Aalborg, Denmark

  • Site not named

    Ballerup Municipality, Denmark

  • Site not named

    Vejle, Denmark

  • Site not named

    Tallinn, Estonia

  • Site not named

    Lodz, Poland

  • Site not named

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.